Comparison of the Effect of Exenatide Versus Sitagliptin on 24-hour Average Glucose in Patients With Type 2 Diabetes on Metformin or a Thiazolidinedione

NCT00729326 · Completed

Last updated 2026-05-28

This clinical trial compares the effects of two diabetes medications, exenatide and sitagliptin, on blood sugar levels over 24 hours in adults with type 2 diabetes who are already taking metformin or a thiazolidinedione.

Status Completed The study has finished.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 83 people

Who can join Ages 18–70 · all sexes

Timeline Started 2008-08 · est. completion 2009-10

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT00729326 ↗

Description as written by the study sponsor.

This study is designed to compare the short-term effects and mechanisms of action of exenatide with those of sitagliptin when either is added to an oral agent(metformin or a thiazolidinedione \[TZD\]) in adult patients with type 2 diabetes mellitus(T2DM) with inadequate glycemic control.

Treatments tested

exenatide also known as Byetta Drug

subcutaneous injection (5mcg or 10mcg), twice a day
sitagliptin also known as Januvia Drug

oral administration (100mg), once a day in the morning
placebo Drug

subcutaneous injection (5mcg or 10mcg), twice a day
placebo Drug

oral administration (100mg), once a day in the morning

Main thing measured	Change in Time-averaged Glucose During a 24 Hour Period
Sponsor	AstraZeneca
Conditions studied	Type 2 Diabetes Mellitus
GLP-1 drugs	exenatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT00729326 ↗